Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEMIO: Neoadjuvant Durvalumab +/- Tremelimumab with ddMVAC in MIUC
NCT03549715Phase 2Active, not recruiting
- Sponsor
- ARTIC
- Start
- Dec 2018
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in urothelial carcinoma (UC), sponsored by ARTIC. Started Dec 2018; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03549715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549715.